Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patient…
$94.23-2.18%
报价 2026-11-16
市值
$7.4B
EV
$7.17B
PE (TTM)
64.5x
预期 PE
–
52 周区间距高点 -4.6%
$37.92$98.76
筛选结果
pipeline · 2026-11-16Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| KNSAKiniksa Pharmaceuticals, Ltd. | $7.4B | -2.2% | – | 54.3% | 64.5x | 49.8x | 36.8x | |
| ALKSAlkermes plc | $7.82B | -1.1% | – | 86.6% | 55.6x | 35.6x | – | |
| CORTCorcept Therapeutics Incorporated | $7.58B | -5.1% | +41.9% | 98.3% | 218.0x | 422.2x | 114.6x | |
| CGONCG Oncology, Inc. Common stock | $7.57B | +14.0% | +107.1% | -102.2% | – | – | – | |
| RYTMRhythm Pharmaceuticals, Inc. | $7.45B | -6.6% | +75.8% | 88.2% | – | – | – | |
| CYTKCytokinetics, Incorporated | $7.41B | -5.3% | +111.1% | -22.3% | – | – | – | |
| ABVXAbivax S.A. | $7.31B | -4.5% | – | 0% | – | – | – | |
| AXSMAxsome Therapeutics, Inc. | $7.21B | -3.3% | +50.1% | 92.6% | – | – | – | |
| IMVTImmunovant, Inc. | $6.89B | -2.6% | -37.1% | 98.6% | – | – | – | |
| 同行中位数 | – | – | +63.0% | 87.4% | 136.8x | 228.9x | 114.6x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。